Price movement over the last 24 hours
Alcon AG vs Conagra Brands Inc — how do they compare? Alcon AG trades at $66.97 (market cap $32.69B), while Conagra Brands Inc trades at $13.89 (market cap $6.71B). The key difference: Alcon AG is far larger — about 4.9× Conagra Brands Inc's market cap, and Conagra Brands Inc pays the higher dividend (9.98%). Which is the better fit depends on your goals.
| ALC | CAG | |
|---|---|---|
Market Cap | $32.69B | $6.71B |
Sector | Health | Consumer Staples |
52-Week High | $92.22 | $20.65 |
52-Week Low | $62.02 | $12.58 |
Enterprise Value | $36.28B | $13.99B |
Dividend Yield | 0.54% | 9.98% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Conagra Brands (CAG) trades at $14.035, down 2.06% on the day, with mixed technical signals and a neutral overall stance. The stock shows modest valuation metrics with a P/E of 10.06 and P/B of 0.81, but faces profitability challenges with a negative net income margin of -0.39%. Recent earnings have been inconsistent, missing estimates in two of the last three quarters. A high dividend yield of approximately 10% is under scrutiny amid concerns over debt levels and slowing growth under new leadership, with the company set to report Q4 earnings on July 15, 2026.
The outlook for CAG is cautious, with potential upside from defensive positioning and dividend income, but significant risks from earnings volatility, high leverage, and dividend sustainability concerns. Investor sentiment is divided, with analysts predominantly neutral, reflecting uncertainty around the company's ability to navigate operational headwinds and debt management effectively.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →